# Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct01229566` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01229566](<https://clinicaltrials.gov/study/NCT01229566>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01229566

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT01229566. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT01229566, source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01229566, source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)
- Primary completion: 2012-07 (anticipated) (ClinicalTrials.gov record NCT01229566, source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)
- Completion: 2012-07 (anticipated) (ClinicalTrials.gov record NCT01229566, source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01229566, source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01229566-2011-11-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): AKR-963
- Lead sponsor: Trygg Pharma, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)

## Provenance

Content hash: ff0003977de3b05c26cbbe0565f78dcecfc2f55d4817402370ed3ef18748118c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
